SUPPLEMENTAL MATERIAL

Efficacy of Human Exposures of Gepotidacin (GSK2140944)
Against Escherichia coli in a Rat Pyelonephritis Model
Methods
Delivery of Infusions:
Flow rates for each treatment were pre-determined in PK studies prior to conducting the efficacy experiments. Note that flow rates depend on multiple factors including (1) syringe size and make; (2) infusion tubing diameter; and (3) concentration of infusion solution. In these studies, all tubing and catheters were made of polyethylene and had an outer diameter of 0.8 mm and inner diameter of 0.4 mm. The concentrations of the solutions for infusion are shown in Supplementary Table 1. Under this set of conditions, the flow rates as shown in Supplementary Table 2 produced the exposure profiles provided in the manuscript figures. The infusion pumps started with an initial flow rate as indicated by time 0; at varying time intervals thereafter, the rate changed to the corresponding value listed in the table. Note that the flow rates for gepotidacin were modified slightly after the first two experiments to more closely reproduce the human profiles. 
FIG S1. Exposure and efficacy in rats infected with E. coli NCTC13441 isolate. (A)
Total and free-drug mean systemic exposure profiles for human target concentrations and those measured in rats during the E. coli NCTC13441 isolate study. (B) Efficacy against E. coli NCTC13441 isolate (uropathogenic sequence type 131 gepotidacin MIC 4 µg/mL). N = 5 to 6 rats/time point; circles show data for individual animals, horizontal lines show the group mean flanked by the standard deviation. hr, hours; LLQ, lower limit of quantification. Daily free-drug AUC0-12 values for the 95% lower bound, the mean profile, and the 95% upper bound were 27, 34, and 40 µg•h/mL for the 1,500-mg exposure profile and 12, 14, and 16 µg•h/mL for the 800-mg exposure profile. hr, hours. 
